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P U B L I S H E D B Y E L S E V I E RLettersCHA2DS2-VASc Score
for Predicting Stroke
and Thromboembolism
in Patients With AF
and Biological
Valve ProsthesisPatients with valvular atrial ﬁbrillation (AF), as
deﬁned in the 2012 European Society of Cardiology
guidelines (those with a valvular prosthesis or rheu-
matic mitral disease) should receive anticoagulation
regardless of the CHA2DS2-VASc score, with vitamin K
antagonist being recommended (1–3). Whether
thromboembolic risk related to bioprosthetic valve
implantation differs from other forms of AF is not
established with certainty. We evaluated the prog-
nostic value of the CHA2DS2-VASc score for throm-
boembolic in AF patients with aortic or mitral
bioprosthesis.
We included all AF patients seen in our institution
between 2000 and 2010 (4) with nonvalvular AF,
according to the European Society of Cardiology
deﬁnition (e.g., those with neither rheumatic valve
disease nor valvular prosthesis) (2), and, among
patients with valvular AF, those with biological valve
prosthesis. The CHA2DS2-VASc score, which has
been validated in nonvalvular AF, was calculated for
each patient (1). We calculated Harrell’s C-statistic
as a measure of model performance.
Among 8,602 AF patients, 8,053 patients (94%) had
nonvalvular AF and 549 (6%) had a bioprosthesis. AF
patients with a bioprosthesis had higher CHA2DS2-
VASc score and were more often treated with oral
anticoagulation. The follow-up was 876  1,048 days
and 681 thromboembolic events were recorded. The
C-statistic for CHA2DS2-VASc score was higher in
patients with nonvalvular AF than in patients with
bioprostheses: 0.64 (95% conﬁdence interval [CI]:
0.63 to 0.65) versus 0.55 (95% CI: 0.50 to 0.59;
p ¼ 0.04). However, the CHA2DS2-VASc score per-
formed similarly in identifying low-risk patients in
the 2 groups: 0.59 (95% CI: 0.58 to 0.60) versus 0.52
(95% CI: 0.47 to 0.56; p ¼ 0.11). There was an increasein the risk of thromboembolic events with increasing
CHA2DS2-VASc score in all AF patients (Figure 1).
Increasing age and CHA2DS2-VASc score were inde-
pendently associated with an increased risk of
thromboembolic events, whilst the presence of bio-
prosthesis was not.
Our population of AF patients is to date the largest
series reporting outcomes in those with bio-
prosthesis. The CHA2DS2-VASc score should theoret-
ically be used for patients with nonvalvular AF (2).
Increasing age and CHA2DS2-VASc score were the
main independent predictors of thromboembolic
events in our study. The score was effective (although
rather poor) to predict thromboembolic risk even in
patients with bioprosthesis and performed similarly
in identifying low-risk patients whether the patients
had bioprosthesis. We conﬁrm both the low throm-
boembolic risk for patients with a low risk score and a
distinctly increased risk for higher scores in the case
of nonvalvular AF. There was a less distinct increase
in the incidence of adverse events in patients with
aortic and/or mitral bioprostheses. This may indicate
that important factors for risk prediction are not
captured by the score. The presence of a bioprosthesis
was not an independent predictive factor for throm-
boembolic events, suggesting that the presence of a
bioprosthesis is not per se a thromboembolic risk
factor.
A yearly rate of thromboembolic events >1% jus-
tiﬁes anticoagulation for patients with nonvalvular
AF (2). Patients with AF and a low theoretical
thromboembolic risk score ﬁtted with a bioprosthesis
had a low annual rate of thromboembolic events even
for those not treated with anticoagulation. These
ﬁndings obtained in smaller subgroups of patients
should be interpreted cautiously but may suggest
that there is no increased risk with the valvular
prosthesis in these AF patients who, in the absence
of bioprosthesis, would be considered at low risk of
thromboembolic events.
Overall, this real-world study lends support to the
use of CHA2DS2-VASc score for the evaluation of AF
patients with bioprostheses. The CHA2DS2-VASc
score was predictive of thromboembolism in AF pa-
tients with a bioprosthesis and performed similarly in
identifying low-risk patients whether patients had
bioprosthesis or nonvalvular AF.
FIGURE 1 Yearly Rate of Thromboembolic Events in AF Patients
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>1 in males, >2 in females. Ao ¼ aortic; AF ¼ atrial ﬁbrillation; NVAF ¼ nonvalvular atrial
ﬁbrillation; VKA ¼ vitamin K antagonist.
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2015;36:1822–30.Effects of P-Selectin
Antagonist Inclacumab
in Patients Undergoing
Coronary Artery Bypass
Graft Surgery
SELECT-CABG TrialDespite unprecedented advances over the last few
decades, saphenous vein graft (SVG) failure remains a
major concern following coronary artery bypass graft
(CABG) surgery (1), and since contemporary treatment
options are limited in these patients, there is an
unmet need for novel therapeutic concepts. Early
evidence to support the adhesion molecule P-selectin
as a potential therapeutic target was provided by
different animal models of vascular inﬂammation
(2,3), as well as phase I clinical studies (4). The recent
SELECT-ACS (Effects of the P-Selectin Antagonist
Inclacumab on Myocardial Damage After Percuta-
neous Coronary Intervention for Non–ST-Segment
Elevation Myocardial Infarction) trial then demon-
strated the efﬁcacy of inclacumab, a human
monoclonal antibody directed against P-selectin, in
reducing myocardial damage following percuta-
neous coronary intervention in patients presenting
with acute coronary syndromes (5). The SELECT-
CABG (Effects of P-Selectin Antagonist Inclacumab
in Patients Undergoing Coronary Artery Bypass
Graft Surgery) trial was therefore designed to
assess the effects of inclacumab on SVG disease
assessed by quantitative coronary angiography 1
year after CABG surgery.
Between December 2010 and May 2012, this pro-
spective, randomized, multicenter, double-blind,
placebo-controlled trial enrolled patients undergoing
CABG surgery (with the use of $1 SVG) at 38 centers in
Canada and the United States. Of 394 patients
